|Videos|April 14, 2017
FDA Approval Sought in Multiple Myeloma, 2017 AACR Annual Meeting Highlights, and More
Advertisement
Patrick Borgen, MD, discusses an FDA approval sought for an agent in multiple myeloma, impressive phase III findings in non—small cell lung cancer, a change in USPSTF recommendations for PSA screening, and highlights from the 2017 AACR Annual Meeting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5































